slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 42,361-42,390
Pages 2,019
Rows per page 30
Component
42,361-42,390 of 60,568
19
The slide outlines a clinical trial design (MMED007) using a timeline-based visualization.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
03
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
09
The slide uses a comparative structure to justify the strategic shift in trial design post-acquisition.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · ComplicationLoop · Cost Of Inaction1 hit
11
The table displays statistical significance (p-values) for multiple clinical endpoints.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
12
TEAE = Treatment-Emergent Adverse Events. Data compares Navacaprant vs Placebo (n=102 each).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
13
Includes a timeline diagram for the randomized, double-blind treatment phase and a summary table of inclusion criteria and endpoints.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
14
The table uses a color-coded legend for 'Degree of preference' (High, Medium, Low).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
15
Includes qualitative expert testimonials regarding pricing and market access.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Market Sizing1 hit
20
The table compares key metrics like EC50, half-life, brain:plasma ratio, selectivity, bioavailability, and molecular weight.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
30
The slide uses a table to demonstrate IP defensibility and a green footer section to categorize the IP strategy.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
31
Clinical trial baseline characteristics table.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
21
This is a standard financial disclosure slide providing a bridge between GAAP loss and non-GAAP adjusted EBITDA.Orthofix | Investor Presentation Deck | 22 slides · Orthofix
Pitch deck Investor relations Beat · Financials1 hit
22
Includes a detailed footnote regarding SeaSpine reclassifications and a paragraph explaining the proforma methodology for the merger.Orthofix | Investor Presentation Deck | 22 slides · Orthofix
Pitch deck Investor relations Beat · Financials1 hit
07
P3 Health Partners | Investor Conference Presentation Deck | 19 slidesP3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Beat · Desire1 hit
19
Includes footnotes explaining transaction costs and other adjustments.P3 Health Partners | Investor Conference Presentation Deck | 19 slides · P3 Health Partners
Conference presentation Investor relations Beat · Satisfaction1 hit
16
The chart highlights the acquisition of Crestmark in 2018.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations 1 hit
19
Standard financial disclosure slide for non-GAAP metrics.Pathward Financial | Investor Presentation Deck | 23 slides · Pathward
Pitch deck Investor relations 1 hit
03
This is a standard IPO/follow-on offering summary table.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
04
The slide uses a structured table format to present key company metrics and status.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
06
The slide uses a Gantt-style visualization for drug development stages.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
08
The slide uses a simple comparison framework to highlight clinical benefits.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
11
The slide uses a comparison table to validate the market potential of the radiopharmaceutical space by highlighting a competitor's success.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · ProblemLoop · Why Now1 hit
13
The slide uses a Kaplan-Meier curve to contrast Lutathera against a control group, highlighting the clinical limitation of the current standard of care.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Loop · Cost Of Inaction1 hit
17
The table specifically highlights that there were zero treatment-related serious adverse events (SAE) and zero discontinuations.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · SolutionLoop · Hypothesis Test1 hit
18
Waterfall plot displays individual patient responses; benchmarking table compares ORR against historical standards.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · SolutionLoop · Hypothesis Test1 hit
20
RayzeBio | IPO Presentation Deck | 41 slidesRayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Beat · SolutionLoop · Hypothesis Test1 hit
21
The slide uses a standard clinical trial flow diagram (Population -> Treatment -> Endpoints -> Crossover).RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank Loop · Hypothesis Test1 hit
24
Includes a visual case study with PET scan images showing tumor reduction.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
32
The slide demonstrates the efficacy and specificity of the drug candidate in a preclinical model.RayzeBio | IPO Presentation Deck | 41 slides · RayzeBio
Pitch deck Investment bank 1 hit
07
The chart tracks subscriber counts in thousands from Q1'21 to Q2'23.Rent The Runway | Results Presentation Deck | 32 slides · Rent The Runway
Conference presentation Investor relations Beat · Need1 hit